source
- Lonza urges biotech firms to prioritize early de-risking to streamline IND pathIn a recent interview, Jaime Okray of Lonza highlighted that emerging biotech companies are shifting focus from pure speed to early identification of development risks as they aim for an IND filing…
- AdvanCell secures $315M Series D to advance lead-based prostate cancer therapyAdvanCell announced a $315 million Series D financing round aimed at supporting development of its lead-based prostate cancer agent and expanding U.S. manufacturing capacity for the radioactive tre…